PHILADELPHIA - White coat hypertension, a condition in which a patient's blood pressure readings are higher when taken at the doctor's office compared to other settings, was originally attributed to the anxiety patients might experience during medical appointments. However, over the years, research has suggested the elevated readings might be a sign of underlying risk for future health problems. A new study led by researchers from Penn Medicine, published today in the Annals of Internal Medicine, revealed that patients with untreated white coat hypertension not only have a heightened risk of heart disease, but they are twice as likely to die from heart disease than people with normal blood pressure.
Researchers also found that patients with white coat hypertension who were taking medication to treat their high blood pressure, called antihypertensives, did not have an increased risk of heart disease or cardiovascular-related death compared to those with normal blood pressure readings.
"Studies suggest that about one in five adults may have white coat hypertension. Our findings underscore the importance of identifying people with this condition," said the study's lead author Jordana B. Cohen, MD, MSCE, an assistant professor in the division of Renal-Electrolyte and Hypertension and a senior scholar in the Center for Clinical Epidemiology and Biostatistics. "We believe individuals with isolated in-office hypertension - those who are not taking blood pressure medication - should be closely monitored for transition to sustained hypertension, or elevated blood pressure both at home and the doctor's office."
High blood pressure, or hypertension, is a defined as a top reading of at least 130 or a bottom one of 80. The condition affects nearly a third of American adults and, if left untreated, increases one's risk for severe complications, including heart attack and stroke. To diagnose and manage the condition, recent hypertension guidelines strongly recommend out-of-office blood pressure monitoring, such as at-home monitoring and ambulatory blood pressure monitoring, which requires patients to wear a portable device that records blood pressure readings over a 24-hour period. However, providers have been slow to adopt this practice due, in part, to skepticism over the usefulness of screening for white coat hypertension given the inconsistent findings - from past studies - and uncertainty around its association with heart disease and death.
To identify the cardiovascular risks of white coat hypertension, the researchers conducted a meta-analysis of 27 studies, comprising more than 60,000 patients, that evaluated the health risks associated with the condition. They found that patients with untreated white coat hypertension had a 36 percent increased risk of heart disease, 33 percent increased risk of death and 109 percent increased risk of death from heart disease.
"Our findings support the pressing need for increased out-of-office blood pressure monitoring nationwide, as it's critical in the diagnosis and management of hypertension," Cohen said. "Simultaneously, we advise individuals with untreated white coat hypertension to engage in lifestyle modifications, including smoking cessation, reduction in their alcohol intake, and making improvements to their diet and exercise regimens. We also caution providers not to over-treat individuals with white coat hypertension who are already on blood pressure medication, as this could lead to dangerously low blood pressures outside of the office and unnecessary side effects from medication."
Researchers noted that future studies are needed to investigate interventions to reduce the cardiac risk of white coat hypertension.
This work was supported, in part, by a grant from the National Institutes of Health (K23-HL133843). Additional Penn authors on the study include Matthew G. Denker, Debbie L. Cohen and Raymond R. Townsend.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center--which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report--Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation's first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.
Annals of Internal Medicine